1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Candidemia – Epidemiology Forecast—2030

Candidemia – Epidemiology Forecast—2030

  • December 2020
  • 76 pages
  • ID: 5993618
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Candidemia – Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Candidemia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Candidemia Disease Understanding
Candidemia is defined as the presence of Candida species in the blood. It is the most common fungal bloodstream infection in hospitalized patients. Mortality is very high. It reaches almost 50% in some studies. Although Candida albicans are still the most common Candida species causing candidemia, in recent years there has been an increase in non-albicans Candida species. The most common risk factors include critical illness and prolonged intensive care unit stay. The presence of a central venous catheter, antibiotic exposure, abdominal surgery (especially if repeated laparotomies or anastomotic leakage is present), malignancy (solid organ and hematologic), acute necrotizing pancreatitis, organ transplant recipients, and total parenteral nutrition are other major risk factors.
Many unmet needs are associated with this disorder; the lack of effectiveness of currently available therapeutics. A progressive shift from C. albicans to non-albicans Candida spp. is also observed in most parts of the world, probably related to the increased exposure to azoles. Therefore new therapies are needed to counter this. Timely diagnosis is one of the most important unmet needs. Therefore, it becomes imperative that such needs are fulfilled to have an efficient and reliable method to treat this disease.

Candidemia Epidemiology
The Candidemia epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of our report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The total incident cases of Candidemia patients are increasing by 7MM during the study period, i.e. 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Candidemia symptoms epidemiology segmented as the Total incident cases of Candidemia, Gender-specific cases of Candidemia, Age-specific cases of Candidemia, Total patients receiving antifungal treatment targeting Candida. The report includes the incident scenario of Candidemia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise - Candidemia Epidemiology
The epidemiology segment also provides the Candidemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total incident cases of Candidemia associated in 7MM countries were 40,655 in 2017.
• As per the estimates, the United States has the largest incident population of Candidemia.
• Among the EU5 countries, Spain had the highest incident cases of Candidemia, followed by Germany. On the other hand, the UK had the lowest incident cases with 2,332 cases in 2017 in EU5.

Scope of the Report
• The Candidemia report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
• The Candidemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Candidemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Candidemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Candidemia.
• The report provides the segmentation of the Candidemia epidemiology by Incident Cases of Candidemia in 7MM.
• The report provides the segmentation of the Candidemia epidemiology by Gender-specific Incident Cases of Candidemia in 7MM.
• The report provides the segmentation of the Candidemia epidemiology by Age-specific Incident Cases of Candidemia in 7MM.
• The report provides the segmentation of the Candidemia epidemiology by Total patients receiving antifungal treatment targeting Candida in 7MM.

Report Highlights

• 11-year Forecast of Candidemia epidemiology
• 7MM Coverage
• Total Incident Cases of Candidemia
• Incident Cases according to segmentation: Gender-specific cases of Candidemia
• Incident Cases according to segmentation: Age-specific cases of Candidemia
• Incident Cases according to segmentation: Total patients receiving antifungal treatment targeting Candida

KOL- Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM concerning the patient population about Candidemia?
• What are the key findings of the Candidemia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Candidemia across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2017–2030)?
• What are the disease risk, burdens, and unmet needs of the Candidemia?
• What are the currently available treatments for Candidemia?

Reasons to buy
The Candidemia epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Candidemia market
• Quantify patient populations in the global Candidemia market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Candidemia therapeutics in each of the markets covered
• Understand the magnitude of Candidemia population by its Incidence cases
• Understand the magnitude of Candidemia population by its Gender-specific cases
• Understand the magnitude of Candidemia population by its Age-specific cases
• Understand the magnitude of Candidemia population by its total patients receiving antifungal treatment targeting Candida
• The Candidemia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Candidemia Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on the skin without causing any problems. However, in certain patients who are at risk, Candida can enter the bloodstream or internal organs and cause an infection. A Candida bloodstream infection, also called candidemia, is the most common form of invasive candidiasis.
Several studies were used to evaluate the hospitalization rate and ICU inpatients. For the US, Healthcare Cost and Utilization Project database was used to project hospital admissions and ICU patients. Regional literature publications were referred for admissions data across EU5 and Japan. It was noted that hospitalization rates were higher in Germany and the United Kingdom, this was also expected as both countries have almost complete health insurance coverage of their populations. National burden studies were referred to get estimates of reported candidemia incidence, most of these studies do not include prophylaxis, pre-emptive, and empirical treatment. The numbers were found to be underestimating the true magnitude of the infections. Across 7MM it was noticed that men are more likely to get infected as compared to women, representing 55%-77% of the total cases. An increased risk was seen in the neonatal population, past 1 year of age risk of infection increased with age, forty-two percent of cases occurred in patients aged ??65 years.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

ADV7103 - Emerging Insight and Market Forecast - 2030

  • $ 3250
  • February 2021
  • 30 pages

“ADV7103 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Renal tubular acidosis (RTA) in 7 Major Markets. A detailed picture ...

  • Europe
  • World
  • Research And Development
  • Clinical Trial
  • Industry analysis
  • Health Expenditure

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on